Unlike Blood Specimen Collection,
Metascreen® Is A Non-Invasive Procedure

Metascreen® is the most comprehensive newborn metabolic screening. Unlike other newborn tests in the market, Metascreen® is a simple and non-invasive urine test to screen more than 100 metabolic disorders without causing any harm or discomfort to your baby. Screening your newborn will facilitate early treatment and prevent long term detrimental effects to your baby’s health.

Unlike blood specimen collection, Metascreen® is a non-invasive procedure

Metascreen® is the most comprehensive newborn metabolic screening. Unlike other newborn tests in the market, Metascreen® is a simple and non-invasive urine test to screen more than 100 metabolic disorders without causing any harm or discomfort to your baby. Screening your newborn will facilitate early treatment and prevent long term detrimental effects to your baby’s health.

Highly Accurate & Specific

Metascreen® uses a gas-chromatography mass spectrometry (GC-MS) technology manufactured by Shimadzu, Japan. After processing the urine specimen through GC-MS, we analyse the GC-MS data using proprietary planar bioinformatics first developed by Japanese researchers. The planar bioinformatics makes use of multiple analytes (metabolites) from more than one biochemical (metabolic) pathway to identify a single metabolic disorder. This means that the results would be more reliable and accurate than traditional technology using mass tandem spectrometry (MS-MS) because MS-MS only uses about 1 or 2 analyte profiles for each disorder, and often, the same analyte profile is used for multiple disorders.

The College Of American Pathologists (CAP) Accredited Laboratory

CAP accreditation is the gold standard for laboratory management and processes, which focuses on key areas such as reliability, correctness and quality care.The accreditation is awarded to facilities after a rigorous on-site inspection as well as examination of the facility’s records and quality management system. Cordlife’s emphasis and commitment to quality is recognized when our facility has been granted the prestigious CAP accreditation.

Highly Reliable Testing Platform

Using FDA-approved GC-MS technology, Metascreen® is a non-invasive urine test that screens more than 100+ metabolic disorders without causing any harm or discomfort to your baby. As many metabolic disorders are organic acid disorders (also known as “organic aciduria”), they can be detected more accurately using urine, based on the abnormal excretion patterns of the metabolites as a result of faulty metabolism caused by the disorder. Because our kidneys can efficiently remove unwanted or toxic metabolites from the blood, such compounds are excreted in large amounts in the urine, but may not be found in significant concentrations in blood.1

The American College of Medical Genetics (ACMG) actually recommends urine organic analysis as the diagnosis step for many of metabolic disorder, should there be a positive newborn screening result using the dried blood spot analysed by tandem mass spectrometry (MS/MS).2,3

 Metascreen®

GC-MS technology

Other test

MS-MS technology

InvasivenessBaby’s urine Baby’s blood from heel prick
NumberMore than 100 disorders Around 20-30 disorders
Accuracy rate 99%3
Higher false positive (0.07- 3.00%)4
Specificity Specific result using multiple analyte profiles Confirmatory test is needed for verification
Time to diagnose From screening and confirmation to diagnosis From screening to confirmation then finally to diagnosis

Enroling Metascreen®

Your baby’s first step to a healthy life. Enrolling Metascreen® for your baby now, the only non-invasive comprehensive newborn screening that detects more than 100+ metabolic disorders.

Metascreen® Enrolment Process

Your baby’s first step to a healthy life. Enrolling Metascreen® for your baby now, the only non-invasive comprehensive newborn screening that detects more than 100+ metabolic disorders.


About 1 in every 1,250 babies5 is expected to be born with an inherited metabolic disorder. Screening your newborn will facilitate early treatment and prevent long term detrimental effects to your baby’s health.


Disclaimer

Metascreen® is a trademark or registered trademark of Cordlife Group Limited, a Singapore Exchange Mainboard listed company. The screening test offered under the brand is conducted by Cordlife (Hong Kong) Ltd., a CAP-accredited laboratory committed to providing early and accurate detection of metabolic disorders in newborn babies. Cordlife (Hong Kong) Ltd. has a quality management system in place to ensure maximum accuracy of screening results. As with any laboratory tests, false positive or false negative results cannot be completely eliminated due to various reasons including but not limited to age of patient at the time of specimen collection, patient’s health status, specimen quality and other variables. Hence, the risk of a disorder should never be precluded solely on the basis of screening. Signs or symptoms observed should be followed up immediately by a professional healthcare provider.

Reference :
1) Evaluation of the 18-month "Pilot Study of Newborn Screening for Inborn Errors of Metabolism" in Hong Kong. HK J Paediatric (New Series). 2020;25:16-22
2) Michael J. Laboratory Medicine Practice Guidelines. Follow-up Testing for Metabolic Diseases Identified by Expanded Newborn Screening Using Tandem Mass Spectrometry. The National Academy of Clinical Biochemistry. 2009
3) Based on internal data, as of June 2020.
4) D. Matern, K. Raymond, S. Tortorelli, et al. Improving NBS Performance: The Mayo Clinic Experience Report.
5) Padilla CD, de la Paz EM. Genetic services and testing in the Philippines. J Community Genet. 2013;4(3):399-411. This cumulative incidence rate is based on the Meta 100+ panel.